Drug intelligence / Profile preview

LS-ABMSC1

Development stage: Unknown
Lead developer: Yamaguchi University
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intra-arterial

Overview

LS-ABMSC1 is an autologous cell therapy product composed of bone marrow-derived mesenchymal stem cells (MSCs). Developed by Shibuya Corporation, it is being investigated for the treatment of decompensated liver cirrhosis. The therapeutic process involves harvesting bone marrow from the patient, expanding the mesenchymal stem cells ex vivo, and then re-administering them to the patient via hepatic arterial infusion. The mechanism of action is thought to involve the secretion of various paracrine factors and cytokines that promote tissue repair, reduce inflammation, and potentially differentiate into hepatocyte-like cells, thereby improving liver function and reducing fibrosis in patients with advanced cirrhosis.

Other names: autologous bone marrow mesenchymal stem cells

Beyond the preview

Go deeper on LS-ABMSC1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LS-ABMSC1.

Explore the full profile